Volume 53, Issue 4, Pages (April 1998)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Volume 63, Issue 3, Pages (March 2003)

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Dyslipidemia in chronic kidney disease: Causes and consequences

Linear and logistic regression analysis

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle

Lipopheresis in the nephrotic syndrome

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Estrogen effects on triglyceride metabolism in analbuminemic rats

New Vitamin D analogs and changing therapeutic paradigms

II. assessment of dyslipidemias

Volume 70, Issue 10, Pages (November 2006)

Robert A. Hegele The American Journal of Human Genetics

Volume 54, Issue 2, Pages (August 1998)

Volume 58, Issue 1, Pages (July 2000)

Kamyar Kalantar-Zadeh Kidney International

Is there a pharmacologic basis for combination renin axis blockade?

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

George A. Kaysen, Burl R. Don

Ian H. de Boer, Rajnish Mehrotra Kidney International

Abnormalities in lipoprotein metabolism in hemodialysis patients

Volume 82, Issue 9, Pages (November 2012)

Comorbidity and confounding in end-stage renal disease

Proinflammatory effects of iron sucrose in chronic kidney disease

Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson

Volume 61, Issue 1, Pages (January 2002)

Volume 55, Issue 3, Pages (March 1999)

Berthil H. C. M. T. Prinsen, Monique G. M

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

New insights into lipid metabolism in the nephrotic syndrome

Blood pressure targets in hemodialysis patients

Volume 67, Issue 1, Pages (January 2005)

Volume 61, Issue 6, Pages (June 2002)

Anne L. M. Vlek, MD, Yolanda van der Graaf, MD, PhD, Maayke A

Volume 54, Issue 2, Pages (August 1998)

Fabia M.O. Pinho, Dirce M.T. Zanetta, Emmanuel A. Burdmann

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Volume 78, Issue 11, Pages (December 2010)

Simvastatin in nephrotic syndrome

Volume 71, Issue 7, Pages (April 2007)

Volume 71, Issue 4, Pages (February 2007)

Mediterranean diets: are they practical in the Western world?

Volume 57, Issue 5, Pages (May 2000)

Volume 72, Issue 4, Pages (August 2007)

Phosphate binders on iron basis: A new perspective?

Organ transplantation goes to the movies

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Volume 65, Issue 4, Pages (April 2004)

Volume 60, Issue 6, Pages (December 2001)

Volume 65, Issue 3, Pages (March 2004)

Volume 69, Issue 10, Pages (May 2006)

Assessing the impact of different imputation methods on serial measures of renal function: The Strong Heart Study N.-M. Shara, J.-G. Umans, W. Wang,

The Case ∣ An Asian boy with proteinuria

Volume 70, Issue 5, Pages (September 2006)

Luís Belo, Ph. D. , Alice Santos-Silva, Ph. D. , Gordon Lowe, M. D

Volume 64, Issue 4, Pages (October 2003)

The International Pediatric Peritonitis Registry: Starting to walk

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients M.R. Marshall, B.G. Byrne, P.G. Kerr,

Volume 60, Issue 2, Pages (August 2001)

Volume 63, Issue 3, Pages (March 2003)

Volume 62, Issue 5, Pages (November 2002)

Presentation transcript:

Volume 53, Issue 4, Pages 994-1001 (April 1998) Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis Monique G. de Sain-van der Velden, George A. Kaysen, Hugh A. Barrett, Frans Stellaard, Mireille M. Gadellaa, Hieronymus A. Voorbij, Dirk-Jan Reijngoud, Ton J. Rabelink Kidney International Volume 53, Issue 4, Pages 994-1001 (April 1998) DOI: 10.1111/j.1523-1755.1998.00831.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Multicompartmental model for apolipoprotein (apo) B100 metabolism. The q1 represents the plasma valine pool (FF = forcing function), d2 is a delay compartment, q3 is the very low density lipoprotein (VLDL) compartment, q4 is the intermediate density lipoprotein (IDL) compartment, and q5 is the low density lipoprotein (LDL) compartment; s2 and s3 represent sampling points for determination of the tracer/tracee ratio of the 13C valine in VLDL apo B100 and in LDL apo B100 compartment respectively. The k-value (2,1) represents the fractional synthesis rate (FSR) of VLDL apo B100, and k-value (0,5) the fractional catabolic rate (FCR) for LDL apo B100. Kidney International 1998 53, 994-1001DOI: (10.1111/j.1523-1755.1998.00831.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Box plots showing the fractional catabolic rate (A; FCR, %/hr) and the absolute synthesis rate (B; ASR, mg/kg/day) of very low density lipoprotein (VLDL) apolipoprotein (apo) B100 in both patients and controls. Shown are the mean (black line), median (dotted line) and range (vertical bars).*P < 0.05. Kidney International 1998 53, 994-1001DOI: (10.1111/j.1523-1755.1998.00831.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Relationship between plasma very low density lipoprotein (VLDL) apolipoprotein (apo) B100 (mg/liter) and the fractional catabolic rate (FCR) of apo B100 (%/hr) in nephrotic patients (A; r2= 0.708, P = 0.0088). The 95% confidence limits of the whole group are shown on either side of the regression line (N = 8). Relationship between plasma VLDL apo B100 (mg/liter) and the absolute synthesis rate (ASR) of VLDL apo B100 (mg/kg/day) for nephrotic patients (B; r2= 0.25, P = 0.21; N = 8). Kidney International 1998 53, 994-1001DOI: (10.1111/j.1523-1755.1998.00831.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 4 Box plots showing the fractional catabolic rate (FCR %/hr; A) and the absolute synthesis rate (ASR) of low density lipoprotein (LDL) apolipoprotein (apo) B100 (mg/kg/day; B) in both patients and controls. Shown are the mean (black line), median (dotted line) and range (vertical bars) (*P = 0.001). Kidney International 1998 53, 994-1001DOI: (10.1111/j.1523-1755.1998.00831.x) Copyright © 1998 International Society of Nephrology Terms and Conditions